Susan S. Pandya

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

J. Baselga, G. Shapiro, E. Kwak, 2010 .

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational new drugs.

A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

A. Jimeno, A. Argiris, L. Wirth, 2016, Cancer.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced

G. Shapiro, E. Kwak, J. Bendell, 2015 .

First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015 .

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.

G. Shapiro, A. Berkenblit, J. Soria, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.